Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
0.6100
Dollar change
-0.0370
Percentage change
-5.72
%
Index- P/E- EPS (ttm)-4.35 Insider Own38.38% Shs Outstand18.18M Perf Week-14.11%
Market Cap10.46M Forward P/E- EPS next Y-2.52 Insider Trans0.00% Shs Float11.20M Perf Month-21.79%
Income-16.80M PEG- EPS next Q-1.09 Inst Own28.50% Short Float0.61% Perf Quarter-45.83%
Sales0.00M P/S- EPS this Y51.67% Inst Trans- Short Ratio0.79 Perf Half Y-82.61%
Book/sh1.06 P/B0.58 EPS next Y-2.23% ROA-36.11% Short Interest0.07M Perf Year-79.02%
Cash/sh1.44 P/C0.42 EPS next 5Y- ROE-72.95% 52W Range0.48 - 8.55 Perf YTD-78.21%
Dividend Est.- P/FCF- EPS past 5Y-103.36% ROI-36.08% 52W High-92.87% Beta1.29
Dividend TTM- Quick Ratio3.17 Sales past 5Y0.00% Gross Margin- 52W Low27.08% ATR (14)0.10
Dividend Ex-Date- Current Ratio3.17 EPS Y/Y TTM45.64% Oper. Margin- RSI (14)42.12 Volatility18.33% 15.25%
Employees71 Debt/Eq0.26 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.00
Option/ShortNo / Yes LT Debt/Eq0.23 EPS Q/Q123.73% Payout- Rel Volume1.21 Prev Close0.65
Sales Surprise- EPS Surprise38.00% Sales Q/Q- EarningsNov 14 BMO Avg Volume86.11K Price0.61
SMA20-4.22% SMA50-23.44% SMA200-73.89% Trades Volume104,607 Change-5.72%
Date Action Analyst Rating Change Price Target Change
Apr-15-21Initiated Ladenburg Thalmann Buy $25
Nov-14-24 06:30AM
Nov-12-24 12:20PM
Oct-16-24 07:05AM
Oct-15-24 07:00AM
Sep-18-24 08:00AM
08:00AM Loading…
Sep-04-24 08:00AM
Sep-03-24 08:00AM
Aug-16-24 10:55AM
Aug-15-24 06:30AM
06:30AM
Aug-08-24 07:00AM
Jul-29-24 07:00AM
Jul-10-24 06:30AM
May-30-24 04:50PM
07:00AM
06:30AM Loading…
May-21-24 06:30AM
May-15-24 07:00AM
May-06-24 07:00AM
Apr-23-24 08:00AM
Apr-18-24 08:00AM
Apr-05-24 09:55AM
Apr-04-24 07:49AM
Apr-03-24 06:30AM
Mar-27-24 06:30AM
Mar-19-24 05:00AM
Mar-18-24 06:30AM
Mar-06-24 07:30AM
Jan-04-24 08:00AM
Nov-30-23 04:15PM
Nov-29-23 06:30AM
06:30AM Loading…
Nov-14-23 06:30AM
Oct-27-23 08:00AM
Oct-18-23 08:00AM
Oct-04-23 06:34AM
Sep-07-23 09:00AM
Sep-06-23 04:05PM
Aug-09-23 06:30AM
Aug-02-23 04:30PM
Jun-08-23 05:00PM
May-31-23 03:00AM
May-15-23 06:30AM
May-12-23 08:00AM
May-08-23 06:30AM
May-05-23 06:30AM
Mar-29-23 06:30AM
Mar-27-23 07:00AM
Feb-22-23 06:35AM
06:30AM
Nov-29-22 09:10AM
Nov-09-22 06:30AM
Nov-02-22 09:00AM
Sep-11-22 07:22AM
Aug-10-22 06:30AM
Aug-07-22 03:17AM
Aug-04-22 11:20AM
Jul-06-22 01:45AM
Jun-28-22 06:30AM
Jun-27-22 06:30AM
May-24-22 01:52AM
May-20-22 08:00AM
May-11-22 06:30AM
May-06-22 07:00AM
May-05-22 08:00AM
Mar-30-22 06:30AM
Mar-23-22 08:00AM
Feb-24-22 08:00AM
Jan-04-22 07:00AM
Nov-17-21 08:00AM
Nov-15-21 06:00AM
Nov-09-21 08:00AM
Oct-25-21 10:00AM
Oct-18-21 07:00AM
Oct-13-21 07:00AM
Sep-02-21 04:05PM
Aug-16-21 06:30AM
Aug-12-21 08:00AM
Jul-26-21 08:13AM
Jun-14-21 06:30AM
Jun-09-21 06:30AM
May-25-21 10:46AM
May-24-21 06:30AM
06:15AM
May-18-21 08:00AM
06:30AM
Apr-20-21 07:00AM
Mar-31-21 06:30AM
05:45AM
Mar-24-21 06:30AM
Mar-02-21 07:00AM
Mar-01-21 07:00AM
Feb-02-21 06:30AM
Jan-04-21 06:30AM
Dec-09-20 04:30PM
Dec-02-20 06:21PM
Nov-16-20 06:30AM
Nov-12-20 06:30AM
06:15AM
Nov-10-20 04:30PM
Nov-05-20 06:30AM
Nov-04-20 06:30AM
BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Gaithersburg, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OrbiMed Israel BioFund GP Limi10% OwnerMay 15 '24Sale0.3824,3449,28013,773,653May 20 04:39 PM